title: Consolidative Radiation in DLBCL: Evidence-Based Recommendations.
abstract: Radiation therapy (RT) has been described as the most effective single agent in the treatment of lymphoma; however, contemporary lymphoma treatment rarely relies on single agents. In the modern era, the selection of appropriate patients for combined modality therapy has become increasingly complex over the last decade with the transition to immunochemotherapy, the emergence of functional imaging for response evaluation, and the improvement in conformal avoidance of normal tissues when delivering RT. Recent evidence demonstrates that selected patients with DLBCL have significantly better outcomes when RT is added to immunochemotherapy; however, there are important knowledge gaps regarding the use of functional imaging to facilitate treatment selection. This article will review the current evidence regarding the optimal use of combined modality therapy for DLBCL.
authors.affiliation: Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. david.hodgson@rmp.uhn.on.ca.|Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada. david.hodgson@rmp.uhn.on.ca.
authors.forename: David C
authors.initials: DC
authors.lastname: Hodgson
authors.affiliation: Lymphoma Unit, Guy's & St Thomas' NHS Foundation Trust, London, UK.
authors.forename: N George
authors.initials: NG
authors.lastname: Mikhaeel
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000639:trends; D003520:Cyclophosphamide; D018572:Disease-Free Survival; D004317:Doxorubicin; D055317:Evidence-Based Practice; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011241:Prednisone; D000069283:Rituximab; D014750:Vincristine
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Combined modality treatment; Diffuse large B-cell lymphoma; Lymphoma; Positron emission topography; Radiation; Radiotherapy